Unlike the present study, which showed null findings, the only other study that used a similar sample of exclusively postmenopausal women with obesity (BMI 30–35 kg/m2) enrolled 28 participants, tested a lower dose of 449 mg EGCG/day for 60 days, and found a significant reduction in serum CRP [21]. Here, CRP is linked to obesity disorder.